Euroapi SA (EAPIN) Stock Forecast & Price Target
EAPIN Analyst Ratings
There are no analyst ratings in the last 3 months.
EAPIN Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Zain Ebrahim | J.P. Morgan | MXN 35.66 | hold | ― | Reiterated | 05/13/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Zain Ebrahim | 05/13/26 | MXN 35.66 | hold | ― | Reiterated | J.P. Morgan |
Best Analysts Covering Euroapi SA
Copying PerPlexity Health Care EU's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +17.10% per trade.
Copying PerPlexity Health Care EU's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +17.10% per trade.
Copying PerPlexity Health Care EU's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +17.10% per trade.
EAPIN Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 0 | 0 | 0 | 0 |
In the current month, EAPIN has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EAPIN average Analyst price target in the past 3 months is ―.
EAPIN Financial Forecast
EAPIN Earnings Forecast
Next quarter’s earnings estimate for EAPIN is -MXN 29.43 with a range of ― to ―. The previous quarter’s EPS was -MXN 29.43. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
EAPIN Sales Forecast
Next quarter’s sales forecast for EAPIN is MXN 7.02B with a range of ― to ―. The previous quarter’s sales results were MXN 7.02B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
